EA201892341A1 - Полиморфные формы 3-[2-бутил-1-(2-диэтиламиноэтил)-1h-бензоимидазол-5-ил]-n-гидроксиакриламида и их применение - Google Patents

Полиморфные формы 3-[2-бутил-1-(2-диэтиламиноэтил)-1h-бензоимидазол-5-ил]-n-гидроксиакриламида и их применение

Info

Publication number
EA201892341A1
EA201892341A1 EA201892341A EA201892341A EA201892341A1 EA 201892341 A1 EA201892341 A1 EA 201892341A1 EA 201892341 A EA201892341 A EA 201892341A EA 201892341 A EA201892341 A EA 201892341A EA 201892341 A1 EA201892341 A1 EA 201892341A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydroxyacrylamide
benzoimidazol
diethylaminoethyl
butyl
application
Prior art date
Application number
EA201892341A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид Дункан
Original Assignee
Мей Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мей Фарма, Инк. filed Critical Мей Фарма, Инк.
Publication of EA201892341A1 publication Critical patent/EA201892341A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201892341A 2016-05-02 2017-05-01 Полиморфные формы 3-[2-бутил-1-(2-диэтиламиноэтил)-1h-бензоимидазол-5-ил]-n-гидроксиакриламида и их применение EA201892341A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02
PCT/US2017/030414 WO2017192451A1 (en) 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Publications (1)

Publication Number Publication Date
EA201892341A1 true EA201892341A1 (ru) 2019-05-31

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892341A EA201892341A1 (ru) 2016-05-02 2017-05-01 Полиморфные формы 3-[2-бутил-1-(2-диэтиламиноэтил)-1h-бензоимидазол-5-ил]-n-гидроксиакриламида и их применение

Country Status (20)

Country Link
US (2) US10626092B2 (cg-RX-API-DMAC7.html)
EP (2) EP3939966A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019514905A (cg-RX-API-DMAC7.html)
KR (1) KR20190005904A (cg-RX-API-DMAC7.html)
CN (1) CN109414425A (cg-RX-API-DMAC7.html)
AR (1) AR108257A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017261218A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018072439A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022011A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018003109A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018012941A2 (cg-RX-API-DMAC7.html)
EA (1) EA201892341A1 (cg-RX-API-DMAC7.html)
ES (1) ES2886495T3 (cg-RX-API-DMAC7.html)
IL (1) IL262578A (cg-RX-API-DMAC7.html)
MA (1) MA44880A (cg-RX-API-DMAC7.html)
MX (1) MX382095B (cg-RX-API-DMAC7.html)
PH (1) PH12018502296B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201809471UA (cg-RX-API-DMAC7.html)
TW (1) TW201741286A (cg-RX-API-DMAC7.html)
WO (1) WO2017192451A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157741A1 (zh) * 2017-02-28 2018-09-07 苏州科睿思制药有限公司 Sb-939的盐的晶型及其制备方法和用途
EP3728205A1 (en) 2017-12-19 2020-10-28 Assia Chemical Industries Ltd Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (zh) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Sb-939的晶型及其制备方法和用途
WO2021217180A1 (en) * 2020-04-22 2021-10-28 Johnson Matthey Public Limited Company Novel forms of pracinostat dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
DE69329856D1 (de) 1992-05-20 2001-02-15 Merck & Co Inc Ester derivate von 4-aza-steroiden
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
PL352835A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
HUP0202180A3 (en) 1999-07-16 2004-10-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
EP1748046A3 (en) 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
EP1472216A2 (en) 2002-02-07 2004-11-03 Axys Pharmaceuticals Novel bicyclic hydroxamates as inhibitors of histone deacetylase
TWI350285B (en) 2002-03-13 2011-10-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CA2478534A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
CN1659161A (zh) 2002-04-16 2005-08-24 帝人株式会社 具有ccr3拮抗作用的哌啶衍生物
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
PT1673349E (pt) 2003-09-22 2010-09-28 S Bio Pte Ltd Derivados benzimidazole: preparação e aplicações farmacêuticas
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
AU2006201177B2 (en) * 2005-09-08 2012-06-14 Mei Pharma, Inc. Heterocyclic compounds
AR055364A1 (es) 2005-09-08 2007-08-22 S Bio Pte Ltd Derivados de benzimidazol
ES2703592T3 (es) * 2007-03-07 2019-03-11 Mei Pharma Inc Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno
CA2927565C (en) 2012-10-30 2021-05-18 Mei Pharma, Inc. Combination therapies

Also Published As

Publication number Publication date
PH12018502296A1 (en) 2019-07-08
WO2017192451A1 (en) 2017-11-09
AR108257A1 (es) 2018-08-01
EP3452035A4 (en) 2019-09-25
US20200317621A1 (en) 2020-10-08
US20190152923A1 (en) 2019-05-23
MX2018013349A (es) 2019-02-20
KR20190005904A (ko) 2019-01-16
EP3452035B1 (en) 2021-07-07
US10626092B2 (en) 2020-04-21
PH12018502296B1 (en) 2022-04-06
EP3452035A1 (en) 2019-03-13
JP2019514905A (ja) 2019-06-06
AU2017261218A1 (en) 2018-11-29
MA44880A (fr) 2021-03-17
ES2886495T3 (es) 2021-12-20
SG11201809471UA (en) 2018-11-29
CL2018003109A1 (es) 2019-04-26
BR112018072439A2 (pt) 2019-02-19
EP3939966A1 (en) 2022-01-19
TW201741286A (zh) 2017-12-01
IL262578A (en) 2018-12-31
CA3022011A1 (en) 2017-11-09
CN109414425A (zh) 2019-03-01
CO2018012941A2 (es) 2018-12-28
MX382095B (es) 2025-03-13

Similar Documents

Publication Publication Date Title
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EP3684418C0 (en) COMPOUNDS FOR THE TREATMENT OF CYSTEAMINE-RESPONSIVE DISORDERS
EP3263132C0 (en) Composition for treating il-6-related diseases
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
EP3573620A4 (en) COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION
MX378739B (es) Compuestos de 2-oxindol.
EA201892203A1 (ru) Оксабороловые сложные эфиры, их применение
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения